All eyes are now on the clinical outcome of the two large studies as the vaccine has been found to be effective against 3 of the four strains of the dengue fever.

The insignificant results of the dengue fever vaccine trial lead by the Sanofi Pasteur pharmaceutical company has not only shocked its clinical professionals but also the pharmaceutical experts of the Biotech field.

And, in an attempt to find out what went off the beam; the researchers are closely monitoring the new dengue vaccine study. The investigators expected to attain at least a 70% efficiency outcome of the study that was carried out on around 4000 patients.

But, the final results that were obtained were a mere 30.2%, which was not even the half of the expected outcome and thus missed the statistical significant mark by a considerable wide margin.

Scott Halstead added that an in depth scientific observation will be needed to understand the exact mechanism of the observed result. He further said that one cannot be very confident that the vaccine will prove to be beneficial in alleviating this disease condition of humans.

The drug company thus, has to wait for the results from the two large phase III clinical trials conducted with 31,000 individuals belonging to the Asian region and Latin America.

The reason for the failure is attributed to the fact that the vaccine produced shielded against 3 of the 4 strains of the dengue virus. But, the vaccine was found to be inactive in producing immune response against the most common strain in people of Thailand as the study was carried out in this area.

All eyes are now on the clinical outcome of the two large studies as the vaccine has been found to be effective against 3 of the four strains of the dengue fever.

For More information please visit our site : http://www.xmaspharmacy.com/